Citius Oncology (CTOR) Total Liabilities (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Total Liabilities data on file, last reported at $65.4 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 17.27% year-over-year to $65.4 million in Q1 2026; TTM through Mar 2026 was $65.4 million, a 17.27% increase from a year earlier, with the FY2025 full-year figure at $56.1 million, up 46.69% from the prior year.
• Total Liabilities for Q1 2026 stood at $65.4 million, up from $51.6 million in the prior quarter.
• Over the last five years, Total Liabilities for CTOR reached as high as $72.6 million in Q4 2023 and fell as low as $22.2 million in Q3 2023.
• Historically, Total Liabilities has averaged $55.4 million across 5 years, with a median of $55.9 million in 2025.
• On a YoY basis, Total Liabilities climbed as much as 72.21% in 2024 and fell as far as 32.26% in 2024.
• Year by year, Total Liabilities stood at $68.2 million in 2022, then advanced by 6.5% to $72.6 million in 2023, then sank by 32.26% to $49.2 million in 2024, then climbed by 4.81% to $51.6 million in 2025, then climbed by 26.9% to $65.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $65.4 million in Q1 2026, $51.6 million in Q4 2025, and $56.1 million in Q3 2025.